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Modulation by calcium of the inhibitor activity of naturally occurring
urinary inhibitors. The possibility that hypercalciuria could cause
calcium stone formation through a mechanism other than by increasing
urinary saturation of stone-forming calcium salts was explored. The
effect of increasing calcium concentration on the inhibitor activity
against the spontaneous precipitation of calcium oxalate was examined
in whole urine (in the presence of naturally occurring inhibitors) and in
synthetic media (with added inhibitors). In II patients with calcium
nephrolithiasis, the induced hypercalciuria from calcium supplementa-
tion (600 mg/day) caused a significant fall in the urinary inhibitory
activity against calcium oxalate precipitation, as shown by a decline in
the formation product ratio from 12.6 1.1 su to 9.6 1.4 (P <
0.005). In order to more fully explore this observation, the effect of
increasing calcium concentration on the inhibitory activities of citrate (2
mM), chondroitin sulfate (0.05 mg/liter) and a heterogeneous group of
naturally-occurring urinary inhibitors (1.0 mg/liter) against calcium
oxalate precipitation was examined in vitro in synthetic solutions. The
inhibitory actions of both citrate and chondroitin sulfate were signifi-
cantly attenuated by increasing calcium concentration from 0.25 m to
6.0 mr'i (P < 0.01). However, raising the calcium concentration in
synthetic media containing a mixture of partially purified urinary
inhibitors produced a significant rise in the urinary inhibitory activity of
this macromolecular mixture (P < 0.01). We conclude that hypercalci-
uria can attenuate the inhibitory activities of citrate and chondroitin
sulfate against calcium oxalate precipitation while at the same time
accentuating the inhibitory activity of naturally-occurring urinary inhib-
itors. The final outcome of these opposing effects on stone formation
will be dependent, in part, on which of these actions exerts a dominant
role in each patient.
The importance of hypercalciuria in calcium stone formation
is well known. Hypercalciuria is frequently encountered in
calcium nephrolithiasis [I]. Our studies have disclosed a direct
correlation between urinary saturation of calcium oxalate or
brushite (CaHPO4 2H20) and urinary calcium concentration
[2]. Despite some reports to the contrary [3], an induced
hypercalciuria from a high calcium intake invariably increases
the urinary saturation of calcium salts [4].
Unfortunately, the degree of urinary saturation with respect
to the stone-forming salts does not correlate well with the
severity of stone-disease. Moreover, the urinary environment
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of normal subjects is often supersaturated with respect to
calcium salts despite the absence of stone disease [2]; thus, a
consideration must also be made of other mechanisms by which
hypercalciuria could cause or contribute to stone formation.
During the course of our studies concerned with the physico-
chemical effects of calcium supplementation, we observed that
while the urinary saturation with respect to calcium oxalate
rose during increased calcium intake, the inhibitory activity of
urine towards calcium oxalate crystallization sometimes de-
clined. This finding suggested that induced hypercalciuria was
reducing the activity of the endogenous urinary inhibitory
constituents. Since it is known that a majority of these inhibi-
tors are negatively charged, we wondered whether the increase
in urinary calcium could attenuate the inhibitory activity of
these negatively charged species by ionic binding.
In the present study, we evaluated the effects of increasing
calcium concentrations on the in vitro inhibitory activity of
three types of inhibitors of calcium oxalate crystallization. The
inhibitors tested were citrate, chondroitin sulfate and a partially
purified preparation of macromolecules obtained from the urine
of non-stone-forming pregnant women.
Methods
Studies in whole urine
The inhibitor activity against calcium oxalate crystallization
in whole urine was examined in samples collected before and
after calcium supplementation and in samples before and fol-
lowing addition of calcium in vitro. Eleven patients with cal-
cium nephrolithiasis of mixed etiology were maintained on a
constant metabolic diet with a daily composition of 400 mg
calcium, 800 mg phosphorus (P), and 100 mEq sodium (Na) and
constant fluids for eight days. During the last four days, they
took calcium gluconate (200 mg Ca three times/day). On Day 4
and on Day 8 (before and following calcium supplementation),
a 24-hour urine sample was collected from each patient for the
measurement of the formation product ratio (FPR) of calcium
oxal ate.
In three normal subjects and seven patients with calcium
nephrolithiasis, a 24-hour urine sample was collected in an
outpatient setting, where they were instructed to adhere to a
diet restricted in Ca (400 mg/day), sodium (100 mEq/day) and
oxalate. The FPR of calcium oxalate was determined in the
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original sample and in the same sample to which additional
calcium (300 mg Calliter) was added as Ca chloride.
The FPR represented the limit of metastability of urine and is
a measure of the inhibitor activity against the spontaneous
precipitation of calcium oxalate [2]. It probably reflects hetero-
geneous nucleation by particle impurities in urine. The FPR was
determined by adding an increasing amount of oxalate as a
solution of sodium oxalate at a constant pH of 6.5 for all urine
tested until spontaneous precipitation of Ca oxalate ensued.
The ratio of the activity product at the point of precipitation and
the activity product at saturation provided the FPR.
Isolation of urinary macrornolecular inhibitors
A 24-hour urine was collected from each of 36 pregnant
women at the second or third trimester. Only clear urine
samples were chosen and kept at 4°C throughout the collection
without any preservatives. Individual urine volumes ranged
from 565 to 3650 mI/day and the total amount was 154 liters. All
the urine was processed by the following procedure after
sequential filtration through a 0.8 cm and a 0,45 m Millipore
filter (Millipore Corporation, Bedford, Massachusetts, USA).
The filtrate was ultrafiltered through a 50,000 dalton hollow
fiber filter (Amicon Corporation, Lexington, Massachusetts,
USA). The retentate was discarded. The collected filtrate was
again ultrafiltered through a 5,000 dalton hollow fiber filter until
the volume was reduced to approximately 100 ml. This reten-
tate was washed with 400 ml distilled water via refiltration
through the 5000 dalton hollow fiber filter four times. The
washed retentate was lyophilized, weighed (1731 mg) and kept
at —20°C, All the procedures described above were performed
in a cold room (4°C).
The lyophilized sample was dissolved in 4 ml of 0.05 M Tris
solution and applied to a 2 x 50 cm DEAE-Sephadex column.
Elution was performed by a linear NaCI gradient (0.05 M Tris
-0.05 M NaCI to 0.05 M Tris - 0.4 M NaCl). One hundred and
sixty fractions (3 ml) were collected. Each fraction was assayed
for protein by the method of Lowry ci al [5], and for inhibitory
activity against spontaneous nucleation of Ca oxalate. The
fractions demonstrating inhibitory activity were pooled togeth-
er, dialyzed (molecular weight cut-off at 6000 to 8000 daltons)
against distilled water for 24 hours, lyophilized, weighed (222
mg) and kept at —20°C.
All of this material was dissolved in 4 ml of 25 m sodium
chloride and applied to a column (2.6 x 100 cm) of Sephadex
0-150 (Pharmacia Fine Chemicals, Uppsala, Sweden). Two
hundred and forty fractions (3 ml) were collected. Again, each
fraction was assayed for protein content and inhibitory activity
as mentioned above. The fractions demonstrating marked inhi-
bition were again pooled, dialyzed, lyophilized and weighed
(26.3 mg) as described above. This material was then subjected
to column chromatography (Sephadex G-100, superfine) as
described above. The fractions demonstrating inhibitory activ
ity were pooled, dialyzed weighed (7.64 mg was obtained) and
stored at —20°C. A portion of this lyophilized sample was used
for the protein and uronic acid [61 determinations and for 12%
SDS-polyacrylamide gel electrophoresis. The remainder was
utilized for measurement of inhibition activity against calcium
oxalate precipitation. The sample used in the inhibitor studies
was not homogenous as disclosed by SDS-polyacrylamide gel
electrophoresis but rather consisted of 6-8 bands in the 12,000
to 40,000 molecular weight range. Although the exact chemical
nature of the inhibitory substances is not known, a portion may
be a glycoprotein as judged by the presence of uronic acid and
protein.
E,ffect of Ca on inhibitory activity of citrate, chondroirin
sulfite, and macromolecules in synthetic solutions
The spontaneous precipitation of calcium oxalate was exam-
ined in control (synthetic) solutions devoid of exogenously
added inhibitors but containing increasing Ca concentrations
over the range of 0.25 m to 6.0 msi. The control solutions,
buffered to pH 6.5 with 5 msi cacodylate, contained sufficient
NaCI to achieve an ionic strength of 0.15 M.
The three test solutions were identical to the control solutions
but contained either 2 m citrate as the sodium salt, chondroi-
tin sulfate (Sigma, St. Louis. Missouri, USA) at a final concen-
tration of 0.05 mg/liter, or urinary macromolecular inhibitor (by
weight, 1 mg/liter). For the test solution containing citric acid,
the amount of added NaCI was reduced in order to maintain the
ionic strength of 0.15 M.
After preparation of each of these test solutions at the various
Ca concentrations described above, increasing amounts of
soluble oxalate (as sodium oxalate) were added. The point of
nucleation after three hours of incubation at 37°C was indicated
by the presence of a visible precipitate, and confirmed by a
sudden decline in the solution concentration of calcium and
oxalate. The point of nucleation, representing the limit of
metastability was assessed from the formation product (FP) of
Ca oxalate rather than FPR [7, 81. The FP represented the
activity product of Ca oxalate at the point of spontaneous
nucleation. Since the components of synthetic media are well
known, unlike in whole urine, a more reliable measure of the
activity product could be measured from synthetic solutions.
Thus, the correction by the empirically derived activity product
at saturation, as in the calculation of the FPR, was not consid-
ered necessary.
Analytical and statistical methods
Oxalate was analyzed by the method of Hodgkinson and
Williams [9] and calcium by atomic absorption spectropho-
tometry. The ionic activities and activity products were calcu-
lated using the computer program of Finlayson [8].
Experiments for limit of metastability were done in replicates
of at least 3. Values are presented as mean SEM. Statistical
significance of the difference in FP between the test and control
solutions at each calcium concentration was determined using
non-parametric analysis and the Kruskal-Wallis test with mul-
tiple comparisons. Significant differences of the change in the
FPR of whole urine was assessed by paired-t analysis.
Results
Effect of dietary Ca on urinary FPR
Figure I summarizes the changes in urinary FPR of calcium
oxalate for the eleven stone-forming patients. As shown, FPR
decreased in all patients except one when dietary calcium was
increased from 400 mg/day to 1000 mg/day (12.6 1.1 to 9.6
1.4, P <0.005).
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Fig. 1. The effect of high dietary Ca intake on the FPRfor Ca oxalate
in 24-hour urine specimens from 11 stone-firming subjects. Each line
connects a study in a separate patient while on the control diet (400 mg
Ca/day) and then subsequently after ingestion of a high Ca diet (1000
mg/day). The mean value for each phase is denoted by the cross bar.
*Significantly different from the control at P < 0.005 by paired-i
analysis.
Effect of calcium added in vitro on urinary FPR
When additional Ca was added to whole urine in vitro, the
FPR of Ca oxalate declined in 7 of 10 samples. The mean value
declined from 9.2 1.6 to 8.0 1.8; however, this decline was
not significant.
Effect of increasing Ca concentration on the inhibitor activity
The FP was unchanged by an increase in calcium concentra-
tion from 0.25 mivi to 6 m in the control solutions without
inhibitors (Table 1). At the lowest Ca concentration of 0.25 mM,
the addition of citrate (2 mM) significantly increased the FP of
Ca oxalate from 1.78 x iO M2 to 2.59 x i0 M2 (P < 0.01).
However, unlike in control solutions, there was a significant fall
in the FP of the citrate-containing solution as the test medium
Ca concentration was increased. Thus, at the highest Ca
concentration (6.0 mM) the FP of the citrate-containing solution
was not significantly different from that of control, but was
significantly less than that of the 0.25 m Ca solution containing
citrate (P < 0.01).
Similarly, the addition of chondroitin sulfate (0.05 mg/liter)
significantly increased the FP of Ca oxalate from 1.78 X 10 M2
to 2.38 x 10-8 M2 (P < 0.01) at a Ca concentration of 0.25 mM.
The FP of Ca oxalate significantly decreased as the concentra-
tion of Ca was increased from 0.25 to 6 mrvt (P < 0.01). The FP
at 6 m was not significantly different from that of the control.
The macromolecular inhibitors exerted a very potent inhibi-
tory action since only I mg of this material per liter of solution
significantly increased the FP of Ca oxalate from 1.78 x IO M2
to 2.03 x 10 M2 (P < 0.01) at a basal Ca concentration of 0.25
mM. In contrast to the other inhibitors, the additional amounts
of calcium progressively and significantly (P < 0.01) raised the
FP x l0 M2
Urinary
Chondroitin macromole-
Ca Citrate SO4 culesm Control 2 mxi 0.05 mg/liter 1.0 mg/liter
0.25 1.78 0.01 2.59 0.06 2.38 0.11 2.03 0.06
0.50 1.89 0.04 2.59 0.06 2.32 0.04 2.12 0.10
0.75 1.83 0.01 2.57 0.06 2.26 0.07a 2.48 016b
1.0 1.79 0.03 2.54 0.Ola 2.28 0.07a 2.32 013b
1.5 1.89 0.01 2.48 0.l2a 2.29 0.06 2.51 0.l5b
2.0 1.81 0.09 2.37 001b 2.11 011b 2.73 020b
4.0 1.81 0.07 2.39 004b 1.97 010b 2.80 022b
6.0 1.86 0.03 1.98 0.03k' 2.00 007b 3.64 020b
ments.
FP values at each calcium concentration for citrate, chondroitin
sulfate and glycoprotein inhibitor were significantly different from 0.25
m calcium value at a P < 0.05 and b P < 0.01 as assessed by multiple
comparisons for the Kruskal-Wallis ANOVA.
FP of Ca oxalate in the presence of the inhibitors. A qualita-
tively similar Ca-dependence of FP was observed when a larger
amount of the inhibitor preparation was used, sufficient to raise
the FP of Ca oxalate at 0.25 m Ca to the same level as was
achieved with citrate (data not shown).
Discussion
The present study was performed to assess whether hyper-
calciuria could contribute to calcium stone formation through
mechanisms other than by raising the urinary saturation of
calcium salts. One possibility is that the urinary inhibitors are
quantitatively or qualitatively deficient in patients with stones.
It is also possible that stone-forming patients may have an
increased activity or excretion of promoters of stone formation
[21. However, a previous search for such a promoter was
unsuccessful [101.
This study was conducted to test an unique hypothesis that
calcium might directly attenuate the activity of certain inhibi-
tors of calcium oxalate crystallization.
This conclusion was supported by our initial studies in whole
urine. When stone-forming patients were given a dietary cal-
cium challenge, the FPR (limit of metastability) of Ca oxalate
was significantly lower during the high calcium phase as com-
pared to the low calcium control phase (Fig. 1). Although this
observation could not be confirmed in vitro by the addition of
exogenous Ca to the urine, a trend toward lower FPRs sug-
gested that a more thorough examination of this potential
attenuation by Ca be undertaken.
One possible mechanism by which Ca could potentially
attenuate inhibitory action would be by ion-pair formation.
Many of the known inhibitors of calcium oxalate crystallization
are negatively charged substances amenable to complexation
by calcium. Small-sized inhibitors, such as pyrophosphate and
citrate, are anions. Many of the reported macromolecular
urinary inhibitors are acidic proteins with a net negative charge
[11] or polysulfated glycosaminoglycans [12] also possessing
negatively charged groups. We therefore chose citrate, chon-
Table 1. Inhibitory activity of citrate, chondroitin sulfate or urinary














All values are expressed as mean SEM of three separate experi-
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droitin sulfate and a partially purified, urinary macromolecular
preparation as a representative spectrum of inhibitors to test
attenuation of their inhibitor activity by calcium. Citrate was
chosen because of its role as a low-molecular weight inhibitor of
Ca oxalate crystallization [13, 14]. Chondroitin sulfate repre-
sents a naturally occurring urinary glycosaminoglycan [121
which we have previously reported to have potent inhibitory
properties for Ca oxalate crystallization [151. There is emerging
evidence that naturally occurring macromolecules, such as
glycoproteins, may be important potent inhibitors of calcium
oxalate crystallization [11].
Addition of citrate to the test solution produced a significant
increase in inhibitory activity as measured by a rise in the FP
for Ca oxalate at the lowest Ca concentration. However, as the
Ca concentration was increased, the FP decreased such that at
the highest Ca concentration (6.0 mM) the FP of the test
solution was not different from that of the control. Based on this
finding, we were not surprised to observe a similar attenuation
of chondroitin sulfate inhibitory activity when an identical
series of experiments was performed.
Totally unexpected, however, was our finding of a significant
augmentation of inhibitory activity for the partially purified,
naturally occurring, macromolecular inhibitor preparation with
increasing Ca concentrations. At present, we cannot explain by
what mechanism Ca is stimulating inhibitory activity of urinary
macromolecules. Preliminary investigations of the obtained
material have suggested that it may contain glycoprotein. This
is based on the observation that our most purified specimen
contained 25% uronic acid and 24% protein by weight. It should
be emphasized that our urinary inhibitor preparation may not
represent all of the endogenous inhibitory activity originally
present in urine, since many of the inhibitory proteins may have
been removed by absorption to the Amicon filtration mem-
brane. Furthermore, our estimates of protein concentration
may be low due to the fact that many inhibitors in urine may not
he detectable by Lowry protein assay. Since we did not do
hydrolysis and amino acid analysis our estimate of 24% protein
by weight may be an underestimate. In addition, the material
used in this study is not homogenous since 6-8 bands in the
12,000 to 40,000 dalton molecular weight range have been
observed on SDS-polyacrylamide gels. However, the presence
of uronic acid, in addition to its chromatographic behavior on
ion-exchange columns, support the presence of negatively
charged moieties as part of its structure. One possible explana-
tion for the lack of inhibitory activity attenuation by Ca is that
Ca binding may promote a conformational change which ex-
poses more negatively charged sites available for Ca binding.
Until a homogenous preparation is obtained and some clue to its
primary or secondary structure obtained, such statements re-
garding its interaction with Ca must remain speculative at best.
The observed differences in attenuation or augmentation of
inhibitory activity by Ca may also explain, in part, the failure to
observe a consistent reduction in the FP when Ca was added to
whole urine in vitro. Since three of these urine specimens were
obtained from normal subjects, the lack of a fall in FP in some
subjects' urines may be reflecting the augmentation of inhibi-
tory activity by naturally occurring inhibitors during Ca addi-
tion. On the other hand, oral administration of Ca caused a
nearly universal fall in FP in stone formers (Fig. I) who may
possess structurally different and functionally deficient glyco-
protein inhibitors in their urine. Previous reports have indicated
that such differences in urinary inhibitors do exist [16, 17].
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